These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25884948)

  • 1. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
    BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Wang F; Gao H; Li C; Bai J; Lu R; Cao L; Wu Y; Hong L; Wu Y; Lan X; Zhang Y
    J Neurooncol; 2014 Jan; 116(1):83-8. PubMed ID: 24135847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
    BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
    Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
    Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
    J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
    Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
    Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
    Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
    Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
    Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
    Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
    Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
    Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
    Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
    Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
    Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
    Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
    Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
    Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
    Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
    Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
    J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
    Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
    Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.